Jacob Philipsen Takes the Helm as Chairman of Norlase's Board of Directors
Norlase, a pioneering company in the field of ophthalmic laser technology, has made a significant leadership change by appointing Jacob Philipsen as the new Chairman of the Board of Directors. This influential shift underscores Norlase's commitment to expanding its presence in the ophthalmic device market and enhancing patient care. Previously, Philipsen was not only the CEO of Advalight but also a co-founder of Norlase. His deep-rooted involvement with the firm positions him strategically to lead Norlase into its next chapter.
Philipsen's impressive academic background includes a PhD in integrated optics from the Technical University of Denmark. With an extensive career in the high-tech medical field, he brings a wealth of executive and board-level experience to Norlase. His previous roles include being the CEO of RSP Systems, a company innovating in diabetes technology, and the President of Sonion MEMS. Moreover, his tenure as Chairman for Danisense and involvement with OCTLight reinforce his credibility and insight in navigating advanced medical technologies.
Oliver Hvidt, CEO and Co-Founder of Norlase, praised Philipsen's contributions, stating that his extensive experience with deep-tech and median-tech scale-up companies makes him the ideal choice for this critical role. Hvidt expressed confidence that under Philipsen's guidance, Norlase will continue to develop innovative solutions that advance the quality of life for patients needing ophthalmic care.
Philipsen’s previous experience as a board member at Norlase gives him an inherent understanding of the company’s vision and operations, which he intends to leverage as Chairman. His leadership comes at a pivotal time when Norlase aims to broaden its offerings in ophthalmology, streamlining practices for providers and enhancing patient experiences through advanced laser solutions.
In light of this transition, David Hardwick, the co-founder who previously held the Chairman position, will still remain involved as a board member. Hvidt noted Hardwick's exceptional contributions over the past decade, stating that his insights will be invaluable as the company pursues its growth initiatives.
Expressing his commitment to the role, Philipsen stated, "It is a great pleasure and privilege to serve on the Board of Norlase. The innovative capacity of the Norlase team and their dedication to improving the quality of life for ophthalmic patients continue to impress me. With their compact, state-of-the-art, easy-to-use solutions, Norlase is truly poised to disrupt the ophthalmic device market to the benefit of both patients and providers. I look forward to working even closer with Oliver, David, and the rest of the team in my new role as Chairman of the Board."
Norlase's innovative lineup includes several next-generation laser solutions, such as LEAF, a laser photocoagulator significantly smaller than existing units, designed to mount directly onto slit lamps. The company is also introducing LION, the first fully integrated green laser, alongside ECHO, the world’s first ultra-portable pattern scanning laser. These products are set to increase operational efficiency while enhancing patient outcomes, aligning with Norlase's mission to provide exceptional eye care solutions.
As Norlase continues to push the boundaries of ophthalmic technology, Jacob Philipsen's appointment as Chairman marks an exciting chapter for the company, promising to usher in a new era of innovative solutions aimed at better patient care and streamlined practices for healthcare providers.
Philipsen's impressive academic background includes a PhD in integrated optics from the Technical University of Denmark. With an extensive career in the high-tech medical field, he brings a wealth of executive and board-level experience to Norlase. His previous roles include being the CEO of RSP Systems, a company innovating in diabetes technology, and the President of Sonion MEMS. Moreover, his tenure as Chairman for Danisense and involvement with OCTLight reinforce his credibility and insight in navigating advanced medical technologies.
Oliver Hvidt, CEO and Co-Founder of Norlase, praised Philipsen's contributions, stating that his extensive experience with deep-tech and median-tech scale-up companies makes him the ideal choice for this critical role. Hvidt expressed confidence that under Philipsen's guidance, Norlase will continue to develop innovative solutions that advance the quality of life for patients needing ophthalmic care.
Philipsen’s previous experience as a board member at Norlase gives him an inherent understanding of the company’s vision and operations, which he intends to leverage as Chairman. His leadership comes at a pivotal time when Norlase aims to broaden its offerings in ophthalmology, streamlining practices for providers and enhancing patient experiences through advanced laser solutions.
In light of this transition, David Hardwick, the co-founder who previously held the Chairman position, will still remain involved as a board member. Hvidt noted Hardwick's exceptional contributions over the past decade, stating that his insights will be invaluable as the company pursues its growth initiatives.
Expressing his commitment to the role, Philipsen stated, "It is a great pleasure and privilege to serve on the Board of Norlase. The innovative capacity of the Norlase team and their dedication to improving the quality of life for ophthalmic patients continue to impress me. With their compact, state-of-the-art, easy-to-use solutions, Norlase is truly poised to disrupt the ophthalmic device market to the benefit of both patients and providers. I look forward to working even closer with Oliver, David, and the rest of the team in my new role as Chairman of the Board."
Norlase's innovative lineup includes several next-generation laser solutions, such as LEAF, a laser photocoagulator significantly smaller than existing units, designed to mount directly onto slit lamps. The company is also introducing LION, the first fully integrated green laser, alongside ECHO, the world’s first ultra-portable pattern scanning laser. These products are set to increase operational efficiency while enhancing patient outcomes, aligning with Norlase's mission to provide exceptional eye care solutions.
As Norlase continues to push the boundaries of ophthalmic technology, Jacob Philipsen's appointment as Chairman marks an exciting chapter for the company, promising to usher in a new era of innovative solutions aimed at better patient care and streamlined practices for healthcare providers.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.